ClinicalTrials.gg
CompletedNCT05646706STEP UPUpdated Apr 23, 2026Results posted

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

A Phase 3 interventional study of Semaglutide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Completed at 107 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,407
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
3rd of 143
1,407 · median 100
Started
2023
with 14 others
Phase 3
42 of 143
10 open now
Registered
55th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 3rd largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 55th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. In the first part of the study, participants will get one injection once a week until they reach the planned dose. The second part of the study, which might last a couple of months, is a transition period, where participant will get three injections, taken right after each other, once a week. The duration of the study intervention (trial product and lifestyle intervention) will be 72 weeks followed by a 9-week follow-up period without study interventions.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age above or equal to 18 years at the time of signing .
  • (BMI) greater than or equal to 30.0 kilogram per square meter (kg/m\^2).
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • greater than or equal to 48 millimoles per mole (mmol/mol) (6.5 percent) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
  • Treatment with glucose-lowering agent(s) within 90 days before screening.
  • A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening irrespective of medical records.
  • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,407 participants (actual)

Study arms

  • Experimental
    Semaglutide 7.2 mg

    Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \[mg\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.

    Drug: Semaglutide

  • Experimental
    Semaglutide 2.4 mg

    Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.

    Drug: Placebo

Interventions

  • Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • DrugPlacebo

    Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

06

What researchers measure

Primary outcomes

  1. Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight

    Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  2. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

    Number of participants who achieve body weight reduction \>=5% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=5% and "no" defines participants who did not achieve body weight reduction \>=5%.

    Time frame: At week 72

Secondary outcomes

  1. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=10% (Yes/no)

    Number of participants who achieve body weight reduction \>=10% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=10% and "no" defines participants who did not achieve body weight reduction \>=10%.

    Time frame: At week 72

  2. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=15% (Yes/no)

    Number of participants who achieve body weight reduction \>=15% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=15% and "no" defines participants who did not achieve body weight reduction \>=15%.

    Time frame: At week 72

  3. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)

    Number of participants who achieve body weight reduction \>=20% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=20% and "no" defines participants who did not achieve body weight reduction \>=20%.

    Time frame: At week 72

  4. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)

    Number of participants who achieve body weight reduction \>=25% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=25% and "no" defines participants who did not achieve body weight reduction \>=25%.

    Time frame: At week 72

  5. Semaglutide 7.2 mg Versus Placebo: Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  6. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Relative Change in Body Weight

    Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  7. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)

    Number of participants who achieve body weight reduction \>=20% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=20% and "no" defines participants who did not achieve body weight reduction \>=20%.

    Time frame: At week 72

  8. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)

    Number of participants who achieve body weight reduction \>=25% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=25% and "no" defines participants who did not achieve body weight reduction \>=25%.

    Time frame: At week 72

  9. Semaglutide 7.2 mg Versus Placebo: Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  10. Semaglutide 7.2 mg Versus Placebo: Change in Body Mass Index (BMI)

    Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  11. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  12. Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (%)

    Change in total fat volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  13. Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (Liters)

    Change in total fat volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  14. Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (%)

    Change in lean body volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  15. Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (Liters)

    Change in lean body volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  16. Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (%)

    Change in visceral fat volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  17. Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (Liters)

    Change in visceral fat volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  18. Pooled Semaglutide Versus Placebo: Change in Body Weight (%)

    Change in body weight (%) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  19. Pooled Semaglutide Versus Placebo: Change in Body Weight (Kg)

    Change in body weight (Kg) from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  20. Semaglutide 7.2 mg Versus Placebo: Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  21. Semaglutide 7.2 mg Versus Placebo: Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  22. Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Milligram Per Deciliter [mg/dL]) - Ratio to Baseline

    Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  23. Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

    Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  24. Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

    Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  25. Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  26. Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL)- Ratio to Baseline

    Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  27. Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L)- Ratio to Baseline

    Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  28. Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mg/dL) - Ratio to Baseline

    Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  29. Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  30. Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mg/dL) - Ratio to Baseline

    Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  31. Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mmol/L) - Ratio to Baseline

    Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  32. Semaglutide 7.2 mg Versus Placebo: Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

    Change in hsCRP (milligram per liter \[mg/L\]) from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  33. Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Lipid-lowering Treatment (Decrease, no Change, Increase)

    Number of participants with change in lipid-lowering treatment from baseline (week 0) is presented in categories as decrease, no change and increase.

    Time frame: At week 72

  34. Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Antihypertensive Treatment (Decrease, no Change, Increase)

    Number of participants with change in antihypertensive treatment from baseline (week 0) is presented in categories as decrease, no change and increase.

    Time frame: At week 72

  35. Semaglutide 7.2 mg Versus Placebo: Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  36. Semaglutide 7.2 mg Versus Placebo: Change in Fasting Plasma Glucose

    Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  37. Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

    Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  38. Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

    Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), End of treatment (week 72)

  39. Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Glycaemic Category (Normo-glycaemia, Pre-diabetes)

    Number of participants with change in glycaemic category from baseline (week 0) to the end of treatment (week 72) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5%

    Time frame: Baseline (week 0), end of treatment (week 72)

  40. Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

    Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

    Time frame: From baseline (week 0) to end of study (week 81)

  41. Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

    Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

    Time frame: From baseline (week 0) to end of study (week 81)

  42. Semaglutide 7.2 mg Versus Placebo: Change in Pulse

    Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.

    Time frame: Baseline (week 0), End of treatment (week 72)

  43. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

    Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.

    Time frame: From baseline (week 0) to end of study (week 81)

  44. Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

    Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

    Time frame: From baseline (week 0) to end of study (week 81)

07

Results

Posted Apr 23, 2026

Participant flow

The trial was conducted at 90 sites in 11 countries as follows: Bulgaria, Canada, Germany, Greece, Hungary, Norway, Poland, Portugal, Slovakia, South Africa, and the Unites States.

Participant flow — Overall Study
MilestoneSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
Started1005201201
Full analysis set1005201201
Safety analysis set1004201201
Magnetic resonance imaging (mri) analysis set4366
Completed959190180
Not completed461121
Withdrew: Withdrawal by subject18616
Withdrew: Lost to follow-up2455
Withdrew: Physician decision400

Outcome measures

PrimarySemaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight

Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Percentage (%) change in body weight
Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight
Percentage (%) change in body weightSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight-19.5 ± 10.6-3.8 ± 7.1
Statistical analysis
  • Semaglutide 7.2 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -14.81 · 95% CI -16.21 to -13.41
PrimarySemaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

Number of participants who achieve body weight reduction \>=5% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=5% and "no" defines participants who did not achieve body weight reduction \>=5%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)
ParticipantsSemaglutide 7.2 mgPlacebo
Yes86263
No88108
Statistical analysis
  • Semaglutide 7.2 mg vs Placebo · Binary regression model · p = <0.0001 · Odds ratio (or): 12.10 · 95% CI 8.32 to 17.61
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=10% (Yes/no)

Number of participants who achieve body weight reduction \>=10% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=10% and "no" defines participants who did not achieve body weight reduction \>=10%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=10% (Yes/no)
ParticipantsSemaglutide 7.2 mgPlacebo
Yes78335
No167136
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=15% (Yes/no)

Number of participants who achieve body weight reduction \>=15% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=15% and "no" defines participants who did not achieve body weight reduction \>=15%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=15% (Yes/no)
ParticipantsSemaglutide 7.2 mgPlacebo
Yes63213
No318158
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)

Number of participants who achieve body weight reduction \>=20% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=20% and "no" defines participants who did not achieve body weight reduction \>=20%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)
ParticipantsSemaglutide 7.2 mgPlacebo
Yes4535
No497166
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)

Number of participants who achieve body weight reduction \>=25% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=25% and "no" defines participants who did not achieve body weight reduction \>=25%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)
ParticipantsSemaglutide 7.2 mgPlacebo
Yes2960
No654171
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Waist Circumference

Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Centimeter (cm)
Semaglutide 7.2 mg Versus Placebo: Change in Waist Circumference
Centimeter (cm)Semaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Waist Circumference-18.0 ± 10.5-5.6 ± 7.4
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Relative Change in Body Weight

Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Percentage (%) change in body weight
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Relative Change in Body Weight
Percentage (%) change in body weightSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Relative Change in Body Weight-19.5 ± 10.6-16.4 ± 9.2
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)

Number of participants who achieve body weight reduction \>=20% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=20% and "no" defines participants who did not achieve body weight reduction \>=20%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=20% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mg
Yes45363
No497126
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)

Number of participants who achieve body weight reduction \>=25% from baseline (week 0) is presented in categories as "yes" or "no" where "yes" defines participants who achieved body weight reduction \>=25% and "no" defines participants who did not achieve body weight reduction \>=25%.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Participants Who Achieve Body Weight Reduction >=25% (Yes/no)
ParticipantsSemaglutide 7.2 mgSemaglutide 2.4 mg
Yes29629
No654160
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Kilograms (kg)
Semaglutide 7.2 mg Versus Placebo: Change in Body Weight
Kilograms (kg)Semaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Body Weight-21.7 ± 12.3-4.3 ± 8.0
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Body Mass Index (BMI)

Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · kilogram per square meter (kg/m^2)
Semaglutide 7.2 mg Versus Placebo: Change in Body Mass Index (BMI)
kilogram per square meter (kg/m^2)Semaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Body Mass Index (BMI)-7.7 ± 4.4-1.5 ± 2.9
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Change in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Kg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Change in Body Weight
KgSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Change in Body Weight-21.7 ± 12.3-18.7 ± 10.4
SecondaryPooled Semaglutide Versus Placebo: Change in Total Fat Volume (%)

Change in total fat volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · % of total fat volume
Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (%)
% of total fat volumePooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (%)-26.9 ± 18.1-2.7 ± 7.3
SecondaryPooled Semaglutide Versus Placebo: Change in Total Fat Volume (Liters)

Change in total fat volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · liters
Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (Liters)
litersPooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Total Fat Volume (Liters)-11.7 ± 8.8-1.5 ± 4.1
SecondaryPooled Semaglutide Versus Placebo: Change in Lean Body Volume (%)

Change in lean body volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · % of lean body volume
Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (%)
% of lean body volumePooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (%)-7.5 ± 7.4-0.4 ± 4.2
SecondaryPooled Semaglutide Versus Placebo: Change in Lean Body Volume (Liters)

Change in lean body volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · liters
Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (Liters)
litersPooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Lean Body Volume (Liters)-1.9 ± 2.0-0.2 ± 0.9
SecondaryPooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (%)

Change in visceral fat volume (%) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · % of visceral fat volume
Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (%)
% of visceral fat volumePooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (%)-33.6 ± 22.9-8.8 ± 16.0
SecondaryPooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (Liters)

Change in visceral fat volume (liters) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · liters
Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (Liters)
litersPooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Visceral Fat Volume (Liters)-1.8 ± 1.3-0.2 ± 0.6
SecondaryPooled Semaglutide Versus Placebo: Change in Body Weight (%)

Change in body weight (%) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · % of body weight
Pooled Semaglutide Versus Placebo: Change in Body Weight (%)
% of body weightPooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Body Weight (%)-18.4 ± 11.9-2.1 ± 4.9
SecondaryPooled Semaglutide Versus Placebo: Change in Body Weight (Kg)

Change in body weight (Kg) from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Kg
Pooled Semaglutide Versus Placebo: Change in Body Weight (Kg)
KgPooled Semaglutide (7.2 mg + 2.4 mg)Placebo
Pooled Semaglutide Versus Placebo: Change in Body Weight (Kg)-20.6 ± 14.7-2.7 ± 6.5
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · millimeters of mercury (mmHg)
Semaglutide 7.2 mg Versus Placebo: Change in Systolic Blood Pressure
millimeters of mercury (mmHg)Semaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Systolic Blood Pressure-10 ± 14-4 ± 12
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · mmHg
Semaglutide 7.2 mg Versus Placebo: Change in Diastolic Blood Pressure
mmHgSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Diastolic Blood Pressure-5 ± 9-1 ± 9
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Milligram Per Deciliter [mg/dL]) - Ratio to Baseline

Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of total cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Milligram Per Deciliter [mg/dL]) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Milligram Per Deciliter [mg/dL]) - Ratio to Baseline0.94 ± 16.71.00 ± 16.8
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of total cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline0.94 ± 16.71.00 ± 16.8
SecondarySemaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline1.08 ± 15.91.02 ± 15.2
SecondarySemaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline1.08 ± 15.91.02 ± 15.2
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL)- Ratio to Baseline

Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL)- Ratio to Baseline
Ratio of LDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL)- Ratio to Baseline0.92 ± 25.50.98 ± 28.6
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L)- Ratio to Baseline

Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L)- Ratio to Baseline
Ratio of LDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L)- Ratio to Baseline0.92 ± 25.50.98 ± 28.6
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mg/dL) - Ratio to Baseline

Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mg/dL) - Ratio to Baseline
Ratio of VLDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mg/dL) - Ratio to Baseline0.76 ± 39.31.00 ± 36.8
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of VLDL cholesterolSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Very Low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline0.76 ± 39.31.00 ± 36.8
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mg/dL) - Ratio to Baseline

Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of triglycerides
Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mg/dL) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mg/dL) - Ratio to Baseline0.76 ± 40.90.99 ± 38.1
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mmol/L) - Ratio to Baseline

Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of triglycerides
Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mmol/L) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Triglycerides (mmol/L) - Ratio to Baseline0.76 ± 40.90.99 ± 38.1
SecondarySemaglutide 7.2 mg Versus Placebo: Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

Change in hsCRP (milligram per liter \[mg/L\]) from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of hsCRP
Semaglutide 7.2 mg Versus Placebo: Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline
Ratio of hsCRPSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline0.38 ± 128.90.89 ± 89.9
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Lipid-lowering Treatment (Decrease, no Change, Increase)

Number of participants with change in lipid-lowering treatment from baseline (week 0) is presented in categories as decrease, no change and increase.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Lipid-lowering Treatment (Decrease, no Change, Increase)
ParticipantsSemaglutide 7.2 mgPlacebo
Decreased80
No change13822
Increased176
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Antihypertensive Treatment (Decrease, no Change, Increase)

Number of participants with change in antihypertensive treatment from baseline (week 0) is presented in categories as decrease, no change and increase.

Time frame:
At week 72
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Antihypertensive Treatment (Decrease, no Change, Increase)
ParticipantsSemaglutide 7.2 mgPlacebo
Decreased576
No change23347
Increased326
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · % of HbA1c
Semaglutide 7.2 mg Versus Placebo: Change in Glycated Haemoglobin (HbA1c)
% of HbA1cSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Glycated Haemoglobin (HbA1c)-0.3 ± 0.30.0 ± 0.3
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Fasting Plasma Glucose

Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · mg/dL
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Plasma Glucose
mg/dLSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Plasma Glucose-11.7 ± 11.9-1.7 ± 11.7
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of fasting serum insulin
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline
Ratio of fasting serum insulinSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline0.61 ± 66.60.90 ± 62.9
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Geometric mean · Ratio of fasting serum insulin
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline
Ratio of fasting serum insulinSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline0.61 ± 66.60.90 ± 62.9
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Glycaemic Category (Normo-glycaemia, Pre-diabetes)

Number of participants with change in glycaemic category from baseline (week 0) to the end of treatment (week 72) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5%

Time frame:
Baseline (week 0), end of treatment (week 72)
Reported as:
Count of participants · Participants
Semaglutide 7.2 mg Versus Placebo: Number of Participants With Change in Glycaemic Category (Normo-glycaemia, Pre-diabetes)
ParticipantsSemaglutide 7.2 mgPlacebo
Normo-glycaemia (week 0) — Normo-glycaemia (week 72)57475
Normo-glycaemia (week 0) — Pre-diabetes (week 72)2120
Normo-glycaemia (week 0) — Diabetes (week 72)02
Pre-diabetes (week 0) — Normo-glycaemia (week 72)29726
Pre-diabetes (week 0) — Pre-diabetes (week 72)5942
Pre-diabetes (week 0) — Diabetes (week 72)03
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

Time frame:
From baseline (week 0) to end of study (week 81)
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)
EventsSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)6430743
SecondarySemaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

Time frame:
From baseline (week 0) to end of study (week 81)
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)
EventsSemaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)10016
SecondarySemaglutide 7.2 mg Versus Placebo: Change in Pulse

Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.

Time frame:
Baseline (week 0), End of treatment (week 72)
Reported as:
Mean · Beats per minute (bpm)
Semaglutide 7.2 mg Versus Placebo: Change in Pulse
Beats per minute (bpm)Semaglutide 7.2 mgPlacebo
Semaglutide 7.2 mg Versus Placebo: Change in Pulse1 ± 10-2 ± 11
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.

Time frame:
From baseline (week 0) to end of study (week 81)
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs
EventsSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs64301133
SecondarySemaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.

Time frame:
From baseline (week 0) to end of study (week 81)
Reported as:
Number · Events
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs
EventsSemaglutide 7.2 mgSemaglutide 2.4 mg
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs10031

Adverse events

Collected over From baseline (week 0) to end of study (week 81). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 7.2 mg0/1,005 (0%)73/1,004 (7.3%)784/1,004 (78.1%)
Semaglutide 2.4 mg0/201 (0%)22/201 (10.9%)140/201 (69.7%)
Placebo0/201 (0%)11/201 (5.5%)117/201 (58.2%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
CholelithiasisHepatobiliary disorders6/10042/2011/201
Abdominal abscessInfections and infestations0/10041/2010/201
Acute kidney injuryRenal and urinary disorders0/10041/2011/201
AdenomyosisReproductive system and breast disorders0/10041/2010/201
Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10041/2010/201
Appendicitis perforatedInfections and infestations0/10041/2010/201
AsthmaRespiratory, thoracic and mediastinal disorders0/10041/2010/201
Atrial flutterCardiac disorders1/10041/2010/201
CellulitisInfections and infestations0/10041/2010/201
Coronary artery diseaseCardiac disorders0/10040/2011/201
Most frequent other events
Showing 10 of 23
Most frequent other events
EventSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
NauseaGastrointestinal disorders439/100477/20127/201
DiarrhoeaGastrointestinal disorders274/100456/20126/201
VomitingGastrointestinal disorders249/100433/20114/201
ConstipationGastrointestinal disorders234/100439/20118/201
NasopharyngitisInfections and infestations82/100415/20125/201
COVID-19Infections and infestations114/100421/20124/201
FatigueGeneral disorders112/100419/2017/201
DyspepsiaGastrointestinal disorders103/100412/2017/201
HeadacheNervous system disorders99/100416/20117/201
EructationGastrointestinal disorders92/100416/2011/201

Baseline characteristics

Full analysis set included all randomized participants. Participants were analysed according to the randomised treatment.

Age, Continuous
Age, Continuous(Years)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Mean47 ± 1246 ± 1248 ± 1247 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Female7531371471037
Male2526454370
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
Hispanic or Latino4412763
Not Hispanic or Latino9611891941344
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 7.2 mgSemaglutide 2.4 mgPlaceboTotal
American Indian or Alaska Native0033
Asian524763
Native Hawaiian or Other Pacific Islander1203
Black or African American821722121
White8591761681203
More than one race91111
Unknown or Not Reported2103
08

Study locations

107 sites
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Chambliss Clinical Trials, LLC
    Montgomery, Alabama 36106, United States
  • Healthscan Clinical Trials,LLC.
    Montgomery, Alabama 36106, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • Florida Inst For Clin Res LLC
    Orlando, Florida 32825, United States
  • Florida Institute For Clinical Research LLC
    Orlando, Florida 32825, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Medical University Of South Carolina
    Charleston, South Carolina 29425, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • Velocity Clin Res, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Medical Center-CRU
    Dallas, Texas 75390, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Sugar Lakes Family Practice PA
    Sugar Land, Texas 77479, United States
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Medical centre Zdrave 1 OOD
    Kozloduy, 3320, Bulgaria
  • Medical center Hippocrates Lukovit EOOD
    Lukovit, 5770, Bulgaria
  • IPMC - Dr. Elizabeta Dimitrova
    Petrich, 2850, Bulgaria
  • Medical center Smolyan clinical research OOD
    Smolyan, 4700, Bulgaria
  • DCC Ascendent OOD
    Sofia, 1202, Bulgaria
  • SGHAT Dr. Shterev EOOD
    Sofia, 1330, Bulgaria
  • Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology
    Sofia, 1407, Bulgaria
  • Medical Centre Medical Arts Medico-dental centre
    Sofia, 1618, Bulgaria
  • Medical Center Medical Plus EOOD
    Varna, 9000, Bulgaria
  • AIPSMC Dr. Evelina Zlatanova EOOD
    Varna, 9010, Bulgaria
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • Nova Scotia Health Authority
    Halifax, Nova Scotia B3H 1V7, Canada
  • Nova Scotia Hlth Halifax
    Halifax, Nova Scotia B3H 1V7, Canada
  • Premier Clinical Trial Research Network (PCTRN)
    Hamilton, Ontario L8L 5G4, Canada
  • Wharton Med Clin Trials
    Hamilton, Ontario L8L 5G8, Canada
  • Wharton Medical Clinic Clinical Trials (Hamilton)
    Hamilton, Ontario L8L 5G8, Canada
  • Hamilton Med Res Group
    Hamilton, Ontario L8M 1K7, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • Ordinace praktického lékaře
    Benátky Na Jizerou, 29471, Czechia
  • Edumed Broumov
    Broumov, 550 01, Czechia
  • Fakultní nemocnice Královské Vinohrady_Praha 10
    Prague, 10034, Czechia
  • Endocare
    Prague, 140 00, Czechia
  • Institut klinické a experimentalni mediciny
    Prague, 14021, Czechia
  • Poliklinika Michnova - Obezitologie
    Prague, 149 00, Czechia
  • Fledip s.r.o.
    Prague, 160 00, Czechia
  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
    Berlin, 13597, Germany
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Praxis Dr. med. M. Esser
    Essen, 45219, Germany
  • Zentrum für klinische Forschung, Dr. med. Lüdemann
    Falkensee, 14612, Germany
  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin
    Münster, 48153, Germany
  • RED-Institut für medizinische Forschung und Fortbildung GmbH
    Oldenburg in Holstein, 23758, Germany
  • Praxis Dr. med. Wenzl-Bauer
    Rehlingen-Siersburg, 66780, Germany
  • Zentrum für klinische Studien Allgäu Oberschwaben
    Wangen, 88239, Germany
  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
    Witten, 58455, Germany
  • University Hospital of Athens ATTIKON
    Athens, Attica 12462, Greece
  • Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
    Athens, 11527, Greece
  • Iatriko Athinon (Athens Medical Canter)
    Athens, 15125, Greece
  • Iatriko Athinon 'Palaiou Falirou'
    Athens, 17562, Greece
  • General Hospital of Lamia
    Lamia, 35100, Greece
  • General Hospital of Thessaloniki 'G. Gennimatas
    Thessaloniki, 54635, Greece
  • AHEPA General University Hospital
    Thessaloniki, 54636, Greece
  • "Ippokrateio" G.H. of Thessaloniki
    Thessaloniki, 54642, Greece
  • "Thermi" Private Hosital
    Thessaloniki, 57001, Greece
  • Lausmed Kft.
    Baja, Bács-Kiskun county 6500, Hungary
  • Belinus Bt.
    Debrecen, Hajdú-Bihar 4025, Hungary
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
    Budapest, 1089, Hungary
  • Bajcsy-Zsilinszky Kórház
    Budapest, 1106, Hungary
  • MED-TIMA Kft.
    Budapest, 1132, Hungary
  • Fejér Megyei Szent György Oktatókórház
    Székesfehérvár, 8000, Hungary
  • Falck Norge AS
    Hamar, 2317, Norway
  • Oslo universitetssykehus HF Aker
    Oslo, 0373, Norway
  • Sykehuset i Vestfold HF, Tønsberg
    Tønsberg, 3116, Norway
  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
    Krakow, Lesser Poland Voivodeship 31-261, Poland
  • NZOZ Przychodnia Specjalistyczna Medica
    Lublin, Lubelski 20-538, Poland
  • NZOZ "CenterMed Lublin" Sp. z o.o.
    Lublin, Lublin Voivodeship 20-044, Poland
  • Kresmed Sp. z o. o.
    Bialystok, Podlaskie Voivodeship 15-481, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • Uniwersyteckie Centrum Kliniczne SUM w Katowicach
    Katowice, 40-752, Poland
  • NBR Polska Tomasz Klodawski
    Warsaw, 00-710, Poland
  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA
    Warsaw, 02-507, Poland
  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
    Senhora Da Hora, Matosinhos, Matosinhos 4464-513, Portugal
  • APDP - Associação Protectora dos Diabéticos de Portugal
    Lisbon, 1250-230, Portugal
  • Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz
    Lisbon, 1349-019, Portugal
  • Hospital da Luz Lisboa, S.A.
    Lisbon, 1500-650, Portugal
  • ULS De São João, E.P.E. - Hospital de São João
    Porto, 4200-319, Portugal
  • Hospital da Luz Arrabida, S.A.
    Vila Nova de Gaia, 4400-346, Portugal
  • MUDr. Dagmar Prokesova, Endokrinologicka ambulancia
    Bratislava, 821 01, Slovakia
  • MEDIMAD, s.r.o., Endokrinologicka ambulancia
    Bratislava, 842 31, Slovakia
  • IN-DIA s.r.o.
    Lučenec, 984 01, Slovakia
  • SIN AZUCAR s.r.o.
    Malacky, 901 01, Slovakia
  • MED-CENTRUM, s.r.o.
    Martin, 036 01, Slovakia
  • SVAJDLEROVA, s.r.o.
    Prešov, 080 01, Slovakia
  • MEDIVASA, s.r.o., Angiologicka ambulancia
    Žilina, 010 01, Slovakia
  • Dom srdca, s.r.o.
    Žilina, 01001, Slovakia
  • Phoenix Pharma
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Medi-Clinic Bloemfontein
    Bloemfontein, Free State 9301, South Africa
  • Soweto Clinical Trial Centre
    Johannesburg, Gauteng 1818, South Africa

Showing the first 100 of 107 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wharton S, Freitas P, Hjelmesaeth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):949-963. doi: 10.1016/S2213-8587(25)00226-8. Epub 2025 Sep 14. PubMed 40961952 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2024, 21 months.

Results were first posted in Apr 2026, 1 year 5 months after primary completion. A results delay was requested in Oct 2025.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 12, 2022
StartActual
Jan 4, 2023
Primary completionActual
Oct 30, 2024
CompletionActual
Nov 26, 2024
Results delay requested
Oct 20, 2025
Results first posted
Apr 23, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05646706
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Jan 4, 2023
Primary completion
Oct 30, 2024
Completion
Nov 26, 2024
Results posted
Apr 23, 2026
Last update
Apr 23, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion